Kotyla, P.J.; Engelmann, M.; Giemza-Stokłosa, J.; Wnuk, B.; Islam, M.A.
Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role? Int. J. Mol. Sci. 2021, 22, 2449.
https://doi.org/10.3390/ijms22052449
AMA Style
Kotyla PJ, Engelmann M, Giemza-Stokłosa J, Wnuk B, Islam MA.
Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role? International Journal of Molecular Sciences. 2021; 22(5):2449.
https://doi.org/10.3390/ijms22052449
Chicago/Turabian Style
Kotyla, Przemysław J., Małgorzata Engelmann, Joanna Giemza-Stokłosa, Bartosz Wnuk, and Md Asiful Islam.
2021. "Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?" International Journal of Molecular Sciences 22, no. 5: 2449.
https://doi.org/10.3390/ijms22052449
APA Style
Kotyla, P. J., Engelmann, M., Giemza-Stokłosa, J., Wnuk, B., & Islam, M. A.
(2021). Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role? International Journal of Molecular Sciences, 22(5), 2449.
https://doi.org/10.3390/ijms22052449